Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
50mg |
|
||
Other Sizes |
|
ln Vitro |
NMDI14 is a nonsense-mediated RNA decay (NMD) inhibitor. If bioactive hemoglobin is produced, treating cells with NMDI14 for six hours can raise PTC 39 β-globin to 12%, a relative increase of four times, which is sufficient to improve the clinical symptoms of thalassemia. NMDI14 treatment for three days did not cause a decrease in cell counts, indicating that NMD can be pharmacologically inhibited without producing minor alterations in proliferation. 941 genes were elevated >1.5-fold by NMDI14. NMDI14 treatment for six hours caused steady-state p53 expression in N417 cells, which was comparable to that in U2OS cells. Without affecting the stability of wild-type p53 in NMDI-treated U2OS cells, NMDI14 dramatically raises the stability of PTC mutant p53 mRNA in N417 cells [1].
|
---|---|
References |
Molecular Formula |
C21H25N3O4S
|
---|---|
Molecular Weight |
415.505903959274
|
Exact Mass |
415.156
|
CAS # |
307519-88-6
|
PubChem CID |
2886617
|
Appearance |
Light yellow to yellow solid powder
|
Density |
1.3±0.1 g/cm3
|
Boiling Point |
658.8±55.0 °C at 760 mmHg
|
Flash Point |
352.2±31.5 °C
|
Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
Index of Refraction |
1.597
|
LogP |
4.3
|
Hydrogen Bond Donor Count |
3
|
Hydrogen Bond Acceptor Count |
6
|
Rotatable Bond Count |
6
|
Heavy Atom Count |
29
|
Complexity |
645
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
QRLPSNLBUMVXBL-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C21H25N3O4S/c1-6-28-21(27)18-12(4)13(5)29-20(18)24-17(25)9-16-19(26)23-15-8-11(3)10(2)7-14(15)22-16/h7-8,16,22H,6,9H2,1-5H3,(H,23,26)(H,24,25)
|
Chemical Name |
ethyl 2-[[2-(6,7-dimethyl-3-oxo-2,4-dihydro-1H-quinoxalin-2-yl)acetyl]amino]-4,5-dimethylthiophene-3-carboxylate
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ≥ 25 mg/mL (~60.17 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 0.83 mg/mL (2.00 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (2.00 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4067 mL | 12.0334 mL | 24.0668 mL | |
5 mM | 0.4813 mL | 2.4067 mL | 4.8134 mL | |
10 mM | 0.2407 mL | 1.2033 mL | 2.4067 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.